MA44145A - Anticorps anti-cd20/anti-cd3 bispécifiques pour traiter la leucémie aiguë lymphoblastique - Google Patents

Anticorps anti-cd20/anti-cd3 bispécifiques pour traiter la leucémie aiguë lymphoblastique

Info

Publication number
MA44145A
MA44145A MA044145A MA44145A MA44145A MA 44145 A MA44145 A MA 44145A MA 044145 A MA044145 A MA 044145A MA 44145 A MA44145 A MA 44145A MA 44145 A MA44145 A MA 44145A
Authority
MA
Morocco
Prior art keywords
antibodies
lymphoblastic leukemia
acute lymphoblastic
treating acute
bispecific
Prior art date
Application number
MA044145A
Other languages
English (en)
Inventor
Carrie Brownstein
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA44145A publication Critical patent/MA44145A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA044145A 2015-12-22 2016-12-21 Anticorps anti-cd20/anti-cd3 bispécifiques pour traiter la leucémie aiguë lymphoblastique MA44145A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562270749P 2015-12-22 2015-12-22
US201662306031P 2016-03-09 2016-03-09

Publications (1)

Publication Number Publication Date
MA44145A true MA44145A (fr) 2018-10-31

Family

ID=57799832

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044145A MA44145A (fr) 2015-12-22 2016-12-21 Anticorps anti-cd20/anti-cd3 bispécifiques pour traiter la leucémie aiguë lymphoblastique

Country Status (14)

Country Link
US (1) US20170174781A1 (fr)
EP (1) EP3394102A1 (fr)
JP (1) JP2019503363A (fr)
KR (1) KR20180087401A (fr)
CN (1) CN108602889A (fr)
AU (1) AU2016378573A1 (fr)
BR (1) BR112018012929A2 (fr)
CA (1) CA3009322A1 (fr)
EA (1) EA201891495A1 (fr)
IL (1) IL260000A (fr)
MA (1) MA44145A (fr)
MX (1) MX2018007756A (fr)
SG (1) SG11201805048SA (fr)
WO (1) WO2017112762A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
AU2015350075B2 (en) 2014-11-17 2021-06-03 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using CD3xCD20 bispecific antibody
MX2019000935A (es) 2016-08-16 2019-07-04 Regeneron Pharma Metodos para cuantificar anticuerpos individuales de una mezcla.
IL312194B1 (en) 2016-10-25 2026-01-01 Regeneron Pharma Methods and systems for analyzing chromatography data
MX2020002850A (es) 2017-09-19 2020-07-24 Regeneron Pharma Metodos para reducir la formacion de particulas y composiciones formadas a partir de estas.
KR20210009421A (ko) * 2018-06-14 2021-01-26 바이오아트라, 엘엘씨 다중 특이적 항체 구조체
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
WO2020028244A1 (fr) * 2018-07-30 2020-02-06 Fedex Corporate Services, Inc. Systèmes, appareil et procédés améliorés permettant l'exploitation automatisée et autonome améliorée d'un équipement de servitude au sol logistique
IL280875B2 (en) * 2018-08-31 2024-12-01 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3874276B1 (fr) 2018-10-31 2023-09-06 Regeneron Pharmaceuticals, Inc. Procédé et système d'identification et de quantification d'une protéine
US11249089B2 (en) 2018-12-12 2022-02-15 Regeneron Pharmaceuticals, Inc. System and method of analysis of a protein using liquid chromatography-mass spectrometry
WO2020232165A1 (fr) * 2019-05-14 2020-11-19 Qlb Biotherapeutics Anticorps anti-cd3 x anti-cd20 bispécifiques et leurs utilisations
CN110563849B (zh) * 2019-08-09 2022-09-09 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd1双特异性抗体
CN110498857B (zh) * 2019-08-09 2022-09-09 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd1双特异性抗体
EP3931303A1 (fr) 2019-12-06 2022-01-05 Regeneron Pharmaceuticals, Inc. Compositions de protéines anti-vegf et leurs procédés de production
TW202135860A (zh) * 2019-12-10 2021-10-01 美商再生元醫藥公司 含有抗ｃｄ２０ｘ抗ｃｄ３雙特異性抗體之穩定調配物
WO2021226444A2 (fr) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Pièges et mini-pièges de vegf et procédés de traitement de troubles oculaires et de cancers
CA3176436A1 (fr) * 2020-05-08 2021-11-11 Tahamtan Ahmadi Anticorps bispecifiques diriges contre cd3 et cd20
US20230322933A1 (en) * 2020-06-04 2023-10-12 Bioinvent International Ab Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
CN112062855B (zh) * 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 一种含有衔接器的药物治疗剂的开发和应用
CN116472060A (zh) * 2020-09-02 2023-07-21 健玛保 抗体疗法
CN114524878B (zh) 2020-11-23 2024-08-02 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
AR127271A1 (es) * 2021-10-09 2024-01-03 Hutchmed Ltd Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos
WO2023086812A1 (fr) 2021-11-11 2023-05-19 Regeneron Pharmaceuticals, Inc. Molécules de liaison cd20-pd1 et leurs méthodes d'utilisation
WO2024123698A1 (fr) 2022-12-08 2024-06-13 Regeneron Pharmaceuticals, Inc. Procédés pour caractériser un domaine fragment cristallisable d'un anticorps bispécifique
WO2025157132A1 (fr) * 2024-01-23 2025-07-31 Wuxi Biologics (Shanghai) Co., Ltd. Anticorps multispécifiques ciblant cd3, cd19 et cd20 et leurs utilisations
TW202540428A (zh) 2024-01-26 2025-10-16 美商雷傑納榮製藥公司 使用漿細胞耗乏劑及／或ｂ細胞耗乏劑遏制宿主抗ａａｖ抗體反應且實現ａａｖ轉導及重複給藥的方法及組成物
US20250242018A1 (en) * 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2460517T3 (es) * 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
CN102209729B (zh) * 2008-11-07 2016-05-25 安进研发（慕尼黑）股份有限公司 小儿急性淋巴细胞白血病的治疗方法
TWI701042B (zh) * 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物

Also Published As

Publication number Publication date
SG11201805048SA (en) 2018-07-30
JP2019503363A (ja) 2019-02-07
AU2016378573A1 (en) 2018-07-19
MX2018007756A (es) 2018-08-09
BR112018012929A2 (pt) 2018-12-11
EA201891495A1 (ru) 2018-11-30
IL260000A (en) 2018-07-31
US20170174781A1 (en) 2017-06-22
WO2017112762A1 (fr) 2017-06-29
CN108602889A (zh) 2018-09-28
CA3009322A1 (fr) 2017-06-29
EP3394102A1 (fr) 2018-10-31
KR20180087401A (ko) 2018-08-01

Similar Documents

Publication Publication Date Title
MA44145A (fr) Anticorps anti-cd20/anti-cd3 bispécifiques pour traiter la leucémie aiguë lymphoblastique
IL266496A (en) Dosage for treatment with bispecific anti-cd20/anti-cd3 antibodies
IL279235A (en) DLL3-CD3 bispecific antibodies
HUE063377T2 (hu) Anti-PD-1 antitestek és bispecifikus anti-CD20/anti-CD3 antitestek kombinációja a rák kezelésére
IL263542A (en) Bispecific antibodies inhibit immunological checkpoint
PL3519437T3 (pl) Przeciwciała dwuswoiste przeciwko p95HER2
HUS2500024I1 (hu) ANTI-PD-1 ellenanyagok
ZA201800534B (en) Bispecific antibodies specific for pd1 and tim3
SI3512547T1 (sl) Anti-PD-1 protitelesa
IL253166B (en) Bispecific antibodies against cd3 and cd20
ZA202004908B (en) Bispecific antibody
GB201710838D0 (en) Bispecific antibodies
HUE063044T2 (hu) Anti-CD38 ellenanyagok akut limfoblasztos leukémia kezelésére
EP3802622A4 (fr) Nouvel anticorps bispécifique anti-cd3/anti-cd20
EP3634998C0 (fr) Anticorps anti cd3 epsilon
IL282355A (en) Bispecific antibodies directed to exosomes
EP3377112A4 (fr) Anticorps bispécifiques bloqués chimiquement
IL269577B (en) Bispecific antibodies anti–pd–l1–anti–tim–3
IL271346A (en) Bispecific antibodies and methods of making and using thereof
SG11201610594WA (en) Anti-il4-il 13 bispecific antibodies
HUE073389T2 (hu) CD20 antitestek
IL272676B (en) Bispecific antibodies against il-4 and il-13
MA41840A (fr) Anticorps bispécifiques anti-cd20 / anti-baff
GB201511196D0 (en) Monoclonal antibodies
HK1262551A1 (en) Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia